IL-27 Mediates Complete Regression of Orthotopic Primary and Metastatic Murine Neuroblastoma Tumors: Role for CD8+ T Cells
Rosalba Salcedo(Frederick National Laboratory for Cancer Research), Jon M. Wigginton(Johns Hopkins University), Robert Kastelein(FX Palo Alto Laboratory), Kimberly Shafer-Weaver(Science Applications International Corporation (United States)), Anatoli Malyguine(Science Applications International Corporation (United States)), Cynthia T. Hahn(Frederick National Laboratory for Cancer Research), Jimmy K. Stauffer(Frederick National Laboratory for Cancer Research), Timothy Back(Science Applications International Corporation (United States)), Erin Lincoln(Science Applications International Corporation (United States)), Julie A. Hixon(Frederick National Laboratory for Cancer Research)
Cited by 160
Related Papers
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
|New England Journal of Medicine|2012|12.6k
Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
|New England Journal of Medicine|2012|8k
Nivolumab plus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2013|4.2k
Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab
|Journal of Clinical Oncology|2014|2.2k